HC Wainwright reiterated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Get Rating) in a research report sent to investors on Friday morning, TipRanks reports. The firm currently has a $35.00 price target on the stock.
A number of other analysts have also recently commented on TPST. Piper Sandler lowered their price target on Tempest Therapeutics from $20.00 to $10.00 in a research note on Friday, May 13th. Zacks Investment Research raised Tempest Therapeutics from a hold rating to a buy rating and set a $4.50 price target for the company in a research note on Friday.
Tempest Therapeutics stock traded down $1.03 during trading hours on Friday, reaching $2.83. 369,039 shares of the company’s stock traded hands, compared to its average volume of 225,385. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.01 and a current ratio of 3.01. Tempest Therapeutics has a fifty-two week low of $2.16 and a fifty-two week high of $41.00. The firm’s 50 day moving average is $3.28 and its 200-day moving average is $4.67.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley lifted its holdings in Tempest Therapeutics by 174.0% during the 3rd quarter. Morgan Stanley now owns 1,989 shares of the company’s stock valued at $29,000 after purchasing an additional 1,263 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Tempest Therapeutics by 26.9% during the 3rd quarter. Renaissance Technologies LLC now owns 34,104 shares of the company’s stock valued at $493,000 after purchasing an additional 7,237 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Tempest Therapeutics by 47.4% during the 4th quarter. Geode Capital Management LLC now owns 34,346 shares of the company’s stock valued at $181,000 after purchasing an additional 11,045 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Tempest Therapeutics during the 3rd quarter valued at $221,000. Finally, Millennium Management LLC acquired a new stake in Tempest Therapeutics during the 3rd quarter valued at $421,000. 34.92% of the stock is owned by institutional investors.
About Tempest Therapeutics (Get Rating)
Tempest Therapeutics Inc, a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors.
- Get a free copy of the StockNews.com research report on Tempest Therapeutics (TPST)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.